Article
Oncology
Amanpreet Kaur Bains, Lena Behrens Wu, Jennifer Riviere, Sandra Rother, Valentina Magno, Jens Friedrichs, Carsten Werner, Martin Bornhaeuser, Katharina S. Goetze, Michael Cross, Uwe Platzbecker, Manja Wobus
Summary: Myelodysplastic syndromes (MDS) are a heterogeneous group of blood malignancies with specific features and a high risk of progression to acute myeloid leukemia. This study found that MSC-derived extracellular matrix (ECM) plays an important role in MDS, with structural alterations observed in MDS ECM and a potential involvement of glycosaminoglycans (GAGs) in this process.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Johann-Christoph Jann, Maximilian Mossner, Vladimir Riabov, Eva Altrock, Nanni Schmitt, Johanna Flach, Qingyu Xu, Verena Nowak, Julia Oblaender, Iris Palme, Nadine Weimer, Alexander Streuer, Ahmed Jawhar, Ali Darwich, Mohammad Jawhar, Georgia Metzgeroth, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak
Summary: Exome sequencing revealed mutations in bone marrow-derived MSCs from patients with myelodysplastic syndrome (MDS), but validation experiments indicate these mutations are secondary to in vitro expansion rather than primary mutations in the BM.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Laura Alves, Vanessa Machado, Joao Botelho, Jose Joao Mendes, Joaquim M. S. Cabral, Claudia L. da Silva, Marta S. Carvalho
Summary: Cell-based therapies using PDLSC may be a promising alternative to MSC(M) and MSC(AT) for periodontal regeneration, as PDLSC showed enhanced proliferative and osteogenic potential. PDLSC expressed osteogenic markers and had higher calcium content and upregulated osteogenic/periodontal genes compared to MSC(M) and MSC(AT). CD146 was specifically expressed by PDLSC, which also had a higher proliferative capacity. However, alkaline phosphatase activity did not increase in PDLSC.
Article
Biochemistry & Molecular Biology
Hongjiao Li, Chenglian Xie, Yurong Lu, Kaijing Chang, Feng Guan, Xiang Li
Summary: This study reveals that plasma exosomal miR92a is significantly upregulated in MDS/AML patients and can interfere with cell resistance to Ara-C by regulating the PTEN and Wnt/β-catenin signaling pathway.
Article
Multidisciplinary Sciences
Nanfang Huang, Yang Song, Wenhui Shi, Juan Guo, Lingyun Wu, Zheng Zhang, Qi He, Xiao Li, Feng Xu
Summary: DHX9 overexpression in myelodysplastic syndromes (MDS) is associated with poor prognosis and high risk of acute myeloid leukemia (AML) transformation. DHX9 is essential for malignant proliferation of leukemia cells. Suppression of DHX9 increases cell apoptosis and sensitizes cells to chemotherapy. Additionally, DHX9 knockdown inactivates PI3K-AKT and ATR-Chk1 signaling, promotes R-loop accumulation, and leads to R-loop-mediated DNA damage.
Article
Medicine, General & Internal
Huan Li, Fang Hu, Robert Peter Gale, Mikkael A. Sekeres, Yang Liang
Summary: Myelodysplastic syndromes (MDS) are a group of blood cancers characterized by dysregulated hematopoiesis and risk of transformation to acute myeloid leukemia. Prognostic systems can predict survival in MDS patients. Treatment goals differ for low-risk and high-risk MDS, with the aim to improve quality of life and prolong survival, respectively. Hematopoietic cell transplantation can cure MDS, but it is not widely used.
NATURE REVIEWS DISEASE PRIMERS
(2022)
Review
Medicine, General & Internal
Chloe Friedrich, Olivier Kosmider
Summary: This article discusses the role of the mesenchymal niche in the pathophysiology of Myelodysplastic syndromes (MDS) and provides an overview of currently available in vitro and in vivo models that can be used to study the effects of the mesenchymal niche on hematopoietic stem cells (HSCs).
Review
Immunology
Likun Zheng, Lei Zhang, Yixuan Guo, Xintong Xu, Zhaoyun Liu, Zhenyu Yan, Rong Fu
Summary: Myelodysplastic syndrome (MDS) is a common hematological malignant disease characterized by abnormal proliferation of malignant hematopoietic stem cells in the bone marrow. The dysfunction of mesenchymal stromal cells (MSCs) in the bone marrow microenvironment plays a critical role in MDS progression through modulation of immune cell function, enabling evasion of immune surveillance by MDS-associated malignant cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Elena Crisa, Paola Boggione, Maura Nicolosi, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Bassel Awikeh, Anna Aspesi, Annalisa Andorno, Renzo Boldorini, Irma Dianzani, Gianluca Gaidano, Andrea Patriarca
Summary: Myelodysplastic syndromes (MDS) arising in the context of inherited bone marrow failure syndromes (IBMFS) present unique challenges in terms of prognosis and treatment, requiring early detection and hematopoietic stem cell transplantation to improve outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Mathieu Meunier, David Laurin, Sophie Park
Summary: The bone marrow niche plays an important role in the development of myelodysplastic syndromes. Mesenchymal stromal cells secrete extracellular vesicles and their miRNA, affecting the fate of hematopoietic stem cells and contributing to leukemogenesis. Extracellular vesicles containing miRNA and proteins can be used as diagnostic and prognostic markers for MDS. Targeting these vesicles or modulating their secretion may offer potential therapeutic directions for MDS.
Article
Biochemistry & Molecular Biology
Agnieszka Kulesza, Katarzyna Zielniok, Jakub Hawryluk, Leszek Paczek, Anna Burdzinska
Summary: This study investigated the effects of nonselective COX inhibitor ibuprofen on human bone marrow MSCs (hBM-MSCs). The results showed that ibuprofen reduced PGE(2) secretion, but did not significantly affect proliferation and migration of MSCs. However, it significantly decreased the secretion of certain pro-regenerative factors.
Article
Multidisciplinary Sciences
Zhenghua Xiong, Yaru Ma, Jia He, Qin Li, Liu Liu, Chunli Yang, Jia Chen, Yi Shen, Xuesong Han
Summary: BMSC-derived apoptotic bodies inhibit fibrosis of HESCs by suppressing the Wnt/β-catenin signaling pathway, offering a novel approach for the clinical treatment of IUAs.
Article
Biochemistry & Molecular Biology
Yang Zheng, Panyang Shen, Mengsha Tong, Hangchao Li, Conglin Ren, Fengqing Wu, Hanyu Li, Huan Yang, Bingbing Cai, Weibin Du, Xing Zhao, Shasha Yao, Renfu Quan
Summary: This study reveals the important role of bone marrow mesenchymal stem cells (BMSCs) in congenital scoliosis (CS). CS-BMSCs showed decreased osteogenic differentiation ability compared to BMSCs from healthy donors. The downregulation of WISP2 was associated with the impaired osteogenic differentiation of CS-BMSCs, and overexpression of WISP2 can promote osteogenesis in CS-BMSCs via the Wnt/beta-catenin pathway. These findings provide new insights into the pathogenesis of CS.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2023)
Article
Pharmacology & Pharmacy
Jinwu Bai, Jianxiang Xu, Kai Hang, Zhihui Kuang, Li Ying, Chenwei Zhou, Licheng Ni, Yibo Wang, Deting Xue
Summary: This study found that glycyrrhizic acid (GA) promotes osteogenic differentiation and enhances calcium deposition by modulating the Wnt/β-catenin signaling pathway. Experimental results demonstrated that GA-GelMA hydrogels accelerate bone healing, showing potential as a cost-effective treatment for bone defects.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Syed A. Mian, Dominique Bonnet
Summary: Myelodysplastic syndromes (MDS) are a group of bone marrow disorders driven by genetic mutations in stem cells, primarily affecting the elderly but also younger individuals. Current treatments have limited success, with allogeneic HSC transplantation being the only potential cure for <5% of patients. The role of the bone marrow microenvironment in MDS development is still not fully understood, but is increasingly recognized as critical in disease progression.
Article
Hematology
Panagiotis T. Diamantopoulos, Argiris Symeonidis, Vasiliki Pappa, Ioannis Kotsianidis, Athanasios Galanopoulos, Charalampos Pontikoglou, Achilles Anagnostopoulos, George Vassilopoulos, Panagiotis Zikos, Eleftheria Hatzimichael, Maria Papaioannou, Aekaterini Megalakaki, Panagiotis Repousis, Maria Kotsopoulou, Maria Dimou, Elena Solomou, Georgios Dryllis, Dimitrios Tsokanas, Menelaos-Konstantinos Papoutselis, Sotirios Papageorgiou, Marie-Christine Kyrtshonis, Alexandra Kourakli, Helen Papadaki, Panayiotis Panayiotidis, Nora-Athina Viniou
Summary: The study found that treatment delays, particularly during the first two cycles, may have an adverse effect on survival for patients with myelodysplastic syndrome receiving 5-azacytidine. Dose reductions were not found to significantly impact prognosis, while delays were shown to affect the time to achieve treatment response for patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Vassiliki Mpakou, Aris Spathis, Anthi Bouchla, Zoi Tsakiraki, Frieda Kontsioti, Sotirios Papageorgiou, Efthymia Bazani, Konstantinos Gkontopoulos, Thomas Thomopoulos, Irene Glezou, Athanasios Galanopoulos, Argiris Symeonidis, Panagiotis T. Diamantopoulos, Nora-Athina Viniou, Christina-Nefeli Kontandreopoulou, Kalliopi Zafeiropoulou, Ioannis Kotsianidis, Eleftheria Lamprianidou, Periklis Foukas, Aristoteles Mpamias, Vasiliki Pappa
Summary: The study suggests a possible association between the Hif-1α signaling pathway and response to 5-AZA therapy in MDS/AML patients, with high Hif-1α mRNA expression correlated with better survival rates and identified as an independent predictor of response to 5-AZA therapy. The data also offer new perspectives on MDS combinational therapies, proposing a potential synergistic activity of 5-AZA and Hif-1α inducers like PHDi.
HEMATOLOGICAL ONCOLOGY
(2021)
Letter
Oncology
Theodoros P. Vassilakopoulos, Alexia Piperidou, Evdoxia Hadjiharissi, Alkistis-Kyra Panteliadou, Fotios Panitsas, Ioannis Vassilopoulos, Eleni Variamis, Dimitrios Boutsis, Michail Michail, Sotirios Papageorgiou, Gerassimos Tsourouflis, Maria Dimou, Stamatis Karakatsanis, Christina Kalpadakis, Niki Stavroyianni, Eirini Katodritou, Maria Kotsopoulou, Ioannis Kotsianidis, Evgenia Verigou, Eleftheria Hatzimichael, Theoni Leonidopoulou, Vassilios Xanthopoulos, Panayiotis Panayiotidis, Kostas Konstantopoulos, Meletios-Athanassios Dimopoulos, Themistoklis Karmiris, Ioannis Batsis, Maria Papaioannou, Gerassimos A. Pangalis, Maria K. Angelopoulou
Article
Oncology
Marina Gerousi, Fotis Psomopoulos, Konstantia Kotta, Maria Tsagiopoulou, Niki Stavroyianni, Achilles Anagnostopoulos, Athanasios Anastasiadis, Maria Gkanidou, Ioannis Kotsianidis, Stavroula Ntoufa, Kostas Stamatopoulos
Summary: The study found that the calcitriol/VDR system is functional in CLL, regulating key signaling pathways for cell survival and proliferation. Microenvironmental signals can modulate VDR expression and function, but calcitriol acts independently, suggesting a potential clinical utility of vitamin D supplementation in CLL patients.
Article
Hematology
Eleftheria Lamprianidou, Chryssoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, Anastasia Filia, Stamatia Laidou, Panayiotis Garantziotis, Theodoros P. Vassilakopoulos, Sotirios G. Papageorgiou, Vassiliki Pappa, Athanasios G. Galanopoulos, Nora Viniou, Evangelia Nakou, Lydia Kalafati, Anastasia Chatzidimitriou, George Kassiotis, Elli Papaemmanuil, Ioannis Mitroulis, Ioannis Kotsianidis
Summary: CD4(+) T cells play a crucial role in immune responses and tumor immunity. A study on patients with high-risk myelodysplastic syndromes undergoing Azacitidine therapy revealed that responders showed a coordinated immune response in CD4(+) T cells, downregulating inflammatory cytokine signaling pathways, particularly IL-6-induced STAT3 phosphorylation in conventional T cells (Tcons). This downregulation was associated with better response and survival, highlighting a potential immune-mediated mechanism of Azacitidine.
Article
Hematology
Theodoros P. Vassilakopoulos, Sotirios G. Papageorgiou, Maria K. Angelopoulou, Sophia Chatziioannou, Vassilios Prassopoulos, Stamatios Karakatsanis, Maria Arapaki, Zois Mellios, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Evangelos Terpos, Evridiki Michali, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Marina P. Siakantaris, Marie-Christine Kyrtsonis, Argyris Symeonidis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Chatziharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Gabriella Gainaru, Catherine Mainta, Panagiotis Tsirigotis, Theodora Assimakopoulou, Pavlina Konstantinidou, Helen Papadaki, Meletios-Athanassios Dimopoulos, Vassiliki Pappa, Themis Karmiris, Paraskevi Roussou, Ioannis Datseris, Panayiotis Panayiotidis, Kostas Konstantopoulos, Gerassimos A. Pangalis, Phivi Rondogianni
Summary: End-of-treatment PET/CT is essential in guiding the decision to omit radiotherapy for patients with primary mediastinal large B-cell lymphoma. Evaluating patients based on the Deauville 5-point scale criteria can predict their freedom from progression. The study suggests that a significant number of PET/CT-negative patients can safely avoid radiotherapy, and emphasizes the importance of not initiating salvage chemotherapy based solely on positive PET/CT results.
ANNALS OF HEMATOLOGY
(2021)
Correction
Biochemistry & Molecular Biology
Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan S. Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max F. Levine, Juan E. Arango, Yangyu Zhou, Francesc Sole, Catherine A. Cargo, Detlef Haase, Maria Creignou, Ulrich Germing, Yanming Zhang, Gunes Gundem, Araxe Sarian, Arjan A. van de Loosdrecht, Martin Jadersten, Magnus Tobiasson, Olivier Kosmider, Matilde Y. Follo, Felicitas Thol, Ronald F. Pinheiro, Valeria Santini, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio P. S. Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori-Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Belickova, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Ades, Matteo Giovanni Della Porta, Alexandra G. Smith, Yesenia Werner, Minal Patel, Agnes Viale, Katelynd Vanness, Donna S. Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellstrom-Lindberg, Seishi Ogawa, Elli Papaemmanuil
Letter
Oncology
Stamatis Karakatsanis, Sotirios G. Papageorgiou, Michail Michail, Maria K. Angelopoulou, Christina Kalpadakis, Theoni Leonidopoulou, Eirini Katodritou, Maria Kotsopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Eleftheria Lakiotaki, Dimitrios Boutsis, George Karianakis, Argiris Symeonidis, Maria Gavriatopoulou, Panayiotis Panayiotidis, Kostas Konstantopoulos, Themis Karmiris, Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos
Correction
Biochemistry & Molecular Biology
Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan S. Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max F. Levine, Juan E. Arango, Yangyu Zhou, Francesc Sole, Catherine A. Cargo, Detlef Haase, Maria Creignou, Ulrich Germing, Yanming Zhang, Gunes Gundem, Araxe Sarian, Arjan A. van de Loosdrecht, Martin Jadersten, Magnus Tobiasson, Olivier Kosmider, Matilde Y. Follo, Felicitas Thol, Ronald F. Pinheiro, Valeria Santini, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio P. S. Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori-Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Belickova, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Ades, Matteo Giovanni Della Porta, Alexandra G. Smith, Yesenia Werner, Minal Patel, Agnes Viale, Katelynd Vanness, Donna S. Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellstrom-Lindberg, Seishi Ogawa, Elli Papaemmanuil
Article
Oncology
Theodoros P. Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, Georgia Kourti, Maria K. Angelopoulou, Fotios Panitsas, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Evangelos Terpos, Maria N. Dimopoulou, Stamatios Karakatsanis, Eurydiki Michalis, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Theophanis Economopoulos, Lydia Kyriazopoulou, Marina P. Siakantaris, Marie-Christine Kyrtsonis, Argyris Symeonidis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Hatjiharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Gabriella Gainaru, Ekaterini Stefanoudaki, Panayiotis Zikos, Panayiotis Tsirigotis, Gerasimos Tsourouflis, Theodora Assimakopoulou, Pavlina Konstantinidou, Helen A. Papadaki, Katerina Megalakaki, Meletios-Athanasios Dimopoulos, Vassiliki Pappa, Themis Karmiris, Paraskevi Roussou, Panayiotis Panayiotidis, Kostas Konstantopoulos, Gerassimos A. Pangalis
Summary: Clinical prognostic factors play a significant role in predicting the outcome of patients with PMLBCL treated with R-CHOP, with two models performing better than established risk scores. These models can help in identifying high-risk subgroups and determining the need for more intensive treatment.
Article
Hematology
Howard S. Oster, Simon Crouch, Alexandra Smith, Ge Yu, Bander Abu Shrkihe, Shoham Baruch, Albert Kolomansky, Jonathan Ben-Ezra, Shachar Naor, Pierre Fenaux, Argiris Symeonidis, Reinhard Stauder, Jaroslav Cermak, Guillermo Sanz, Eva Hellstrom-Lindberg, Luca Malcovati, Saskia Langemeijer, Ulrich Germing, Mette Skov Holm, Krzysztof Madry, Agnes Guerci-Bresler, Dominic Culligan, Laurence Sanhes, Juliet Mills, Ioannis Kotsianidis, Corine van Marrewijk, David Bowen, Theo de Witte, Moshe Mittelman
Summary: The study proposes a noninvasive web-based application utilizing gradient boosted models to help exclude or diagnose myelodysplastic syndrome (MDS). By utilizing demographic, clinical, and laboratory variables, the application can accurately predict or exclude MDS in 86% of patients with unexplained anemia. The developed application shows stability and accuracy in predicting MDS and provides physicians with a convenient noninvasive diagnostic tool.
Article
Hematology
Maria Stamou, Stergios Intzes, Marianthi Symeonidou, Ioanna Bazntiara, Zoe Bezirgiannidou, Aikaterini Pentidou, Christina Misidou, Konstantinos Liapis, Dimitrios Margaritis, Ioannis Kotsianidis, Emmanouil Spanoudakis
Summary: The incidence of thrombophilia is increased among women with RF, but the severity or type of thrombophilia is not related to pregnancy outcome. Age is an important factor influencing live birth rate in this population.
ACTA HAEMATOLOGICA
(2022)
Article
Oncology
Christina-Nefeli Kontandreopoulou, Panagiotis T. Diamantopoulos, Andreas Giannopoulos, Argiris Symeonidis, Ioannis Kotsianidis, Vasiliki Pappa, Athanasios Galanopoulos, Panayiotis Panayiotidis, Maria Dimou, Elena Solomou, Theodoros Loupis, Katerina Zoi, Nefeli Giannakopoulou, Georgios Dryllis, Sevastianos Hatzidavid, Nora-Athina Viniou
Summary: The study found that in MDS treatment, RNR expression is correlated with clinical outcomes, with low RRM1 levels associated with RRM1 methylation status affecting patient response to 5-azacytidine treatment. Splicing factor mutations may be related to a decrease in RRM1 mRNA levels.
LEUKEMIA & LYMPHOMA
(2022)
Review
Oncology
Ilias Pessach, Theodoros Spyropoulos, Eleftheria Lamprianidou, Ioannis Kotsianidis
Summary: Measurable residual disease (MRD) is an important prognostic and predictive biomarker in acute myeloid leukemia (AML), but its use is hindered by the lack of standardization in available methodologies. Multiparameter flow cytometry (MFC) offers a highly effective technology for studying both antitumor immunity and leukemic clone dynamics, leading to the development of improved MRD assessment.
Letter
Hematology
Konstantinos Liapis, Menelaos Papoutselis, Georgios Vrachiolias, Christina Misidou, Emmanouil Spanoudakis, Zoe Bezirgiannidou, Aikaterini Pentidou, Theocharis Konstantinidis, Ioannis Kotsianidis
ANNALS OF HEMATOLOGY
(2021)